433938-43-3

Upstream product

• 433938-42-2 (2R)-[3-chloro-5-(difluoromethoxy)-phenyl](hydroxy)acetic acid 
• 218598-31-3 H-Aze-Pab(Teoc) 
• 218598-31-3 H-Aze-Pab(Teoc) 

Downstream Products

• 433938-79-5 Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-Aze-Pab(OMe,Teoc) 
• 433938-45-5 Ph(3-Cl)(5-OCHF₂)-(R)-CH(OH)C(O)-Aze-Pab(OH, Teoc) 
• 433938-45-5 Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-Aze-Pab(OH,Teoc) 

Relevant academic research and scientific papers

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION

According to the present invention there is provided an immediate release pharmaceutical formulation comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituen

MODIFIED RELEASE PHARMACEUTICAL FORMULATION

A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituents;R2 represents hydrogen, hydroxy, methoxy